Kırıkkale University, Faculty of Medicine, Department of Cardiology - Kırıkkale, Turkey.
Kırıkkale University, Faculty of Medicine, Department of Oncology - Kırıkkale, Turkey.
Rev Assoc Med Bras (1992). 2024 Sep 16;70(9):e20240517. doi: 10.1590/1806-9282.20240517. eCollection 2024.
Breast cancer is among the highest causes of morbidity and mortality in women. Trastuzumab therapy, which is known to be significantly cardiotoxic, is mainly used to treat patients with resistant breast cancer, including estrogen receptor-positive type. We aimed to show the effects of trastuzumab therapy on endothelial functions of breast cancer patients.
In this study, a total of 26 participants (24 female and 2 male patients, minimum age: 38 years, maximum age: 79 years, and mean age 57.3±12.7 years) were enrolled in the study. For the statistical evaluation of data, we classified the participants of the study as follows: Pretreatment: Before trastuzumab therapy; Treatment Period 1: 1 month after the first dose of trastuzumab; Treatment Period 2: 4 months after the first dose of trastuzumab; Treatment Period 3: 12 months after the first dose of trastuzumab. We conducted repeated-measures analysis of variance (Greenhouse-Geisser) and paired-sample t-tests to statistically compare the groups using flow-mediated dilation measurements.
We determined that there are statistically significant differences between flow-mediated hyperemia and ratio values (flow-mediated dilation) of the groups (p<0.009 and p<0.001, respectively).
Our data indicate that trastuzumab therapy could have negative effects on endothelial functions in breast cancer patients.
乳腺癌是女性发病率和死亡率最高的疾病之一。曲妥珠单抗治疗对心脏有明显的毒性作用，主要用于治疗包括雌激素受体阳性型在内的耐药性乳腺癌患者。我们旨在研究曲妥珠单抗治疗对乳腺癌患者血管内皮功能的影响。
本研究共纳入 26 名参与者（24 名女性和 2 名男性患者，最小年龄 38 岁，最大年龄 79 岁，平均年龄 57.3±12.7 岁）。为了对数据进行统计评估，我们将研究参与者分为以下三组：预处理：曲妥珠单抗治疗前；治疗期 1：首次曲妥珠单抗治疗后 1 个月；治疗期 2：首次曲妥珠单抗治疗后 4 个月；治疗期 3：首次曲妥珠单抗治疗后 12 个月。我们采用重复测量方差分析（Greenhouse-Geisser）和配对样本 t 检验对各组的血流介导扩张测量值进行统计学比较。
我们发现各组间血流介导充血和比值（血流介导扩张）值存在统计学显著差异（p<0.009 和 p<0.001）。
我们的数据表明，曲妥珠单抗治疗可能对乳腺癌患者的血管内皮功能产生负面影响。
